Printer Friendly

UPJOHN TO EXPAND PHARMACEUTICAL CHEMICAL PLANT IN FRANCE

 KALAMAZOO, Mich., Jan. 5 /PRNewswire/ -- The Upjohn Company (NYSE: UPJ) announced today that it is expanding its pharmaceutical chemical plant in Val de Reuil (Normandy), France. Upjohn's French pharmaceutical manufacturing plant is also located at Val de Reuil.
 The expansion, which is expected to become operational in 1995, will integrate the most advanced technologies in the areas of quality control, productivity and environmental protection. The total investment is estimated to be $35 million.
 "This expansion will allow Upjohn to manufacture the active ingredients for currently marketed pharmaceutical products outside the U.S. and potential new products with initial sales outside the U.S.," said William U. Parfet, president. "It will also provide us with the capability to meet an increased demand for non-U.S. clinical supplies that will allow us to conduct the development and synthesis of important new molecules from Upjohn's research laboratories located in Tsukuba, Japan, and Crawley, England."
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 1/5/93
 /CONTACT: John P. Lambrechts of The Upjohn Company, 616-323-7076/
 (UPJ)


CO: The Upjohn Company ST: Michigan IN: MTC SU:

ML -- DE004 -- 1564 01/05/93 09:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 5, 1993
Words:224
Previous Article:HEILIG-MEYERS REPORTS DECEMBER SALES RESULTS
Next Article:SAFEGUARD BUSINESS SYSTEMS ANNOUNCES ALLIANCE WITH PLATINUM SOFTWARE CORP.
Topics:


Related Articles
ROBERTS PHARMACEUTICAL ACQUIRES TWO MARKETED NON-PRESCRIPTION PRODUCTS FROM UPJOHN
UPJOHN COMPLETES ACQUISITION OF PAKISTAN COMPANY
FDA ADVISORY COMMITTEE RECOMMENDS LUVOX (FLUVOXAMINE) TABLETS FOR OBSESSIVE COMPULSIVE DISORDER
UPJOHN TO WHOLLY OWN JAPAN UPJOHN LIMITED
UPJOHN STARTS CONSTRUCTION OF CHINA JOINT VENTURE PLANT
INCYTE AND UPJOHN SIGN $20 MILLION DATABASE ACCESS AGREEMENT
PHARMACIA AND UPJOHN MERGER OF EQUALS TO FORM NEW TOP-10 GLOBAL PHARMACEUTICAL COMPANY
PHASE III CLINICAL TRIALS OF ELTANOLONE STOPPED TEMPORARILY
PHARMACIA & UPJOHN DEDICATES JOINT VENTURE PLANT IN CHINA
A test of internalization theory and internationalization theory: the Upjohn Company.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters